Literature DB >> 10824110

Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor.

Y Wang1, J Dang, H Wang, H Allgayer, G A Murrell, D Boyd.   

Abstract

We have previously defined the promoter of human urokinase-type plasminogen activator receptor (uPAR) gene in a 188-bp fragment between bases -141 and +47 relative to the translation start site. Here, we report that a novel nuclear factor-kappaB (NF-kappaB)-like sequence (5'-GGGAGGAGTC-3') at -45 is located in the uPAR promoter and one of the two DNase I-protected regions, region I between bases -51 and -30. This NF-kappaB-like motif differs at positions 7-9 from the decameric consensus sequences of NF-kappaB (5'-GGGRNNYYCC-3' where R indicates A or G, Y indicates C or T, and N indicates any nucleotide) and at positions 1 and 7-9 from the kappaB-like motifs (5'-HGGARNYYCC-3' where H indicates A, C, or T, R indicates A or G, Y indicates C or T, and N indicates any nucleotide). Nuclear extracts from HCT116 cells contain proteins that specifically bind to the NF-kappaB-like site at position -45. Mutation of the NF-kappaB-like motif decreased the binding of transcription factor NF-kappaB and reduced the uPAR promoter activity in comparison with the wild-type sequences. Co-transfection with a dominant negative I-kappaB kinase-2 expression vector reduced uPAR promoter activity by 65-75%. These results demonstrate that a previously uncharacterized NF-kappaB motif is required for uPAR promoter activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10824110     DOI: 10.1046/j.1432-1327.2000.01350.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  19 in total

1.  Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression.

Authors:  Shoshana Greenberger; Irit Adini; Elisa Boscolo; John B Mulliken; Joyce Bischoff
Journal:  Angiogenesis       Date:  2010-09-25       Impact factor: 9.596

Review 2.  Regulation of cell signalling by uPAR.

Authors:  Harvey W Smith; Chris J Marshall
Journal:  Nat Rev Mol Cell Biol       Date:  2010-01       Impact factor: 94.444

3.  Transcription factor MEF2C suppresses endothelial cell inflammation via regulation of NF-κB and KLF2.

Authors:  Zhenhua Xu; Takeshi Yoshida; Lijuan Wu; Debasish Maiti; Liudmila Cebotaru; Elia J Duh
Journal:  J Cell Physiol       Date:  2015-06       Impact factor: 6.384

4.  Transgenic mice demonstrate novel promoter regions for tissue-specific expression of the urokinase receptor gene.

Authors:  Heng Wang; John Hicks; Parham Khanbolooki; Sun-Jin Kim; Chunhong Yan; Yao Wang; Douglas Boyd
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

5.  STAT5a activation mediates the epithelial to mesenchymal transition induced by oncogenic RhoA.

Authors:  Salvador Aznar Benitah; Pilar F Valerón; Hallgeir Rui; Juan Carlos Lacal
Journal:  Mol Biol Cell       Date:  2003-01       Impact factor: 4.138

6.  A selective small-molecule nuclear factor-kappaB inhibitor from a high-throughput cell-based assay for "activator protein-1 hits".

Authors:  Moon-Il Kang; Curtis J Henrich; Heidi R Bokesch; Kirk R Gustafson; James B McMahon; Alyson R Baker; Matthew R Young; Nancy H Colburn
Journal:  Mol Cancer Ther       Date:  2009-03-03       Impact factor: 6.261

7.  Upregulation of cyclooxygenase-2 is associated with activation of the alternative nuclear factor kappa B signaling pathway in colonic adenocarcinoma.

Authors:  Guang Shi; Dong Li; Jinling Fu; Yan Sun; Yarong Li; Rongfeng Qu; Xin Jin; Dongfu Li
Journal:  Am J Transl Res       Date:  2015-09-15       Impact factor: 4.060

8.  Regulation of u-PAR gene expression by H2A.Z is modulated by the MEK-ERK/AP-1 pathway.

Authors:  Santosh Chauhan; Douglas D Boyd
Journal:  Nucleic Acids Res       Date:  2011-09-21       Impact factor: 16.971

9.  The prognostic value of the suPARnostic ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms.

Authors:  Uffe V Schneider; Rikke L Nielsen; Court Pedersen; Jesper Eugen-Olsen
Journal:  BMC Infect Dis       Date:  2007-11-16       Impact factor: 3.090

10.  AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation.

Authors:  Maria Victoria Maliandi; Ana Mato-Berciano; Luciano Sobrevals; Gaël Roué; Anabel José; Cristina Fillat
Journal:  Mol Cancer       Date:  2015-07-31       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.